Alnylam Pharmaceuticals Inc
Research Alnylam Pharmaceuticals Inc (ALNY) on Bullrun: valuation model: 28.5% overvalued, market cap USD 39.19B, P/E 69.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALNY
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Valuation signal28.5% overvalued
- Market capUSD 39.19B
- P/E69.7
- Financial periodFY2025
- RevenueUSD 3.71B
- Revenue growth65.2%
- Net incomeUSD 313.75M
- Free cash flowUSD 465.38M
- Gross margin81.8%
Valuation Snapshot
Bullrun's latest valuation model marks Alnylam Pharmaceuticals Inc as 28.5% overvalued; latest market cap is USD 39.19B; P/E is 69.7.
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
Frequently asked questions
Is Alnylam Pharmaceuticals Inc overvalued or undervalued?
Bullrun's valuation model currently marks Alnylam Pharmaceuticals Inc as 28.5% overvalued.
What is Alnylam Pharmaceuticals Inc's market cap?
Alnylam Pharmaceuticals Inc's market capitalization is USD 39.19B.
What is Alnylam Pharmaceuticals Inc's P/E ratio?
Alnylam Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 69.7.
What does Alnylam Pharmaceuticals Inc do?
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis;